Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rineterkib - Novartis

Next Previous
X
Search
Drug Profile

Rineterkib - Novartis

Alternative Names: ERK-IN-1; LTT-462

Latest Information Update: 28 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Amines; Antineoplastics; Benzamides; Bromobenzenes; Cyclohexanols; Fluorobenzenes; Pyrazines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Myelofibrosis
  • No development reported Colorectal cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Aug 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease) in Germany (PO, Capsule)
  • 01 Aug 2022 Novartis suspends a phase-I/II clinical trials in Myelofibrosis (Combination therapy) in Australia, Spain, Belgium, Canada, Denmark, Hungary, Israel, Italy, Japan, South Korea, the Netherlands, Romania, Russia, Sweden, Switzerland, Turkey, the UK and Germany (PO) due to challenges to identify the patient population as specified by protocol (NCT04097821)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top